Skip to main content
Quest PharmaTech Inc. logo

Quest PharmaTech Inc. — Investor Relations & Filings

Ticker · QPT ISIN · CA74836M1068 TSXV Manufacturing
Open in API
Filings indexed 107 across all filing types
Latest filing 2025-05-28 Regulatory Filings
Country CA Canada
Listing TSXV QPT

About Quest PharmaTech Inc.

https://questpharmatech.com/

Quest PharmaTech Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics. The company's pipeline targets applications in cancer treatment, dermatology, and wound healing, utilizing both proprietary technologies, such as transdermal delivery systems, and strategic investments. A core proprietary asset is the antibody Mab AR 9.6, licensed for targeted cancer therapy against truncated O-glycan on MUC16. Quest also maintains significant ownership interests in associated entities, including OncoVent, and holds convertible bond interests in OncoQuest Pharmaceuticals, Inc. (OQP). These OQP bonds are planned to be exchanged into shares of Canaria Bio, a company developing immunotherapy assets, providing Quest with an expected ownership stake of approximately 23% in Canaria Bio upon conversion.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV1 “Certification of Annual Filings” under Canadian National Instrument 52-109. It is not the full annual report or MD&A themselves but a statutory certificate by the CEO confirming the integrity of those filings. It is a regulatory filing that does not fit into specific categories like Annual Report (10-K), MD&A, Audit Report, or Dividend Notice, so the correct classification is the general Regulatory Filings category (RNS).
2025-05-28 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 92% confidence The document is a completed regulatory form (Form 13-501F1) filed with the Alberta Securities Commission to certify participation fee calculations and issuer details. It is not an annual or interim report, earnings release, management change notice, or other specialized category, but rather a routine securities commission filing. This fits the fallback category “Regulatory Filings (RNS).”
2025-05-28 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a NI 52-109 venture issuer certification form (Form 52-109FV2) signed by the CFO certifying that the interim financial report and interim MD&A have been reviewed, and contains no misrepresentations. It is not the interim report itself (financial statements or MD&A), but rather a regulatory certificate filing. Therefore, it does not fit categories like Interim Report (IR) or MD&A (MDA) but is a general regulatory filing under Canadian securities rules. This matches the fallback category Regulatory Filings (RNS).
2024-12-23 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 82% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate under Canadian NI 52-109, certifying that the interim financial report and interim MD&A for the period ended October 31, 2024 were reviewed and fairly presented. It is not the interim report itself (which would be an IR), nor is it simply announcing a report’s publication (RPA). This is a required regulatory certificate, which falls into the general Regulatory Filings category (RNS).
2024-12-23 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled “Management’s Discussion & Analysis for the nine months ended October 31, 2024” and contains detailed narrative of financial results, performance, liquidity, risks, accounting policies, etc., which matches the definition of a Management Report (MD&A). It is not the full interim report (it lacks the actual financial statements) but solely the MD&A section. Therefore, it fits the Management Reports (MDA) category.
2024-12-23 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Quest PharmaTech Inc. for the three and nine months ended October 31, 2024. It contains comprehensive financial statements (Statement of Financial Position, Income/Loss, Changes in Equity, Cash Flows) and detailed notes. It is a formal financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2024-12-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.